Abstract
Extracellular adenosine is produced with increased metabolic activity or stress, acting as a paracrine signal of cellular effort. Adenosine receptors are most abundant in the brain, where adenosine acts through inhibitory A(1) receptors to decrease activity/noise and through facilitatory A(2A) receptors (A(2A)R) to promote plastic changes in physiological conditions. By bolstering glutamate excitotoxicity and neuroinflammation, A(2A)R also contribute to synaptic and neuronal damage, as heralded by the neuroprotection afforded by the genetic or pharmacological blockade of A(2A)R in animal models of ischemia, traumatic brain injury, convulsions/epilepsy, repeated stress or Alzheimer's or Parkinson's diseases. A(2A)R overfunction is not only necessary for the expression of brain damage but is actually sufficient to trigger brain dysfunction in the absence of brain insults or other disease triggers. Furthermore, A(2A)R overfunction seems to be an early event in the demise of brain diseases, which involves an increased formation of ATP-derived adenosine and an up-regulation of A(2A)R. This prompts the novel hypothesis that the evaluation of A(2A)R density in afflicted brain circuits may become an important biomarker of susceptibility and evolution of brain diseases once faithful PET ligands are optimized. Additional relevant biomarkers would be measuring the extracellular ATP and/or adenosine levels with selective dyes, to identify stressed regions in the brain. A(2A)R display several polymorphisms in humans and preliminary studies have associated different A(2A)R polymorphisms with altered morphofunctional brain endpoints associated with neuropsychiatric diseases. This further prompts the interest in exploiting A(2A)R polymorphic analysis as an ancillary biomarker of susceptibility/evolution of brain diseases.